Closures a sign of Novartis minimizing production in Switzerland

The recently announced site closures by Novartis ($NVS) in Switzerland may be an indication that the country's pharmaceutical industry is being forced to move away from mass production. "High quality products that require a lot of research and development will always be made in Switzerland while finished products will be made elsewhere," said Julius Bär economist Janwillem Acket in Le Temps. Story

Suggested Articles

Transporting pharmaceutical products at <-60C for more than 96 hours has seemed an insurmountable challenge. TOWER’s solution has solved the problem.

Roche will spend $500 million for a new global manufacturing logistics hub in Canada that will eventually employ 500 workers in Ontario.

Fledgling Indiana CDMO Incog BioPharma Services is shelling out $60 million to get its first manufacturing facility off the ground.